Title:Is Biotechnological Next-Generation Therapeutics Promising Enough in Clinical Development to Treat Advanced Colon Cancer?
Volume: 22
Issue: 10
Author(s): Sarubala Malayaperumal, Sushmitha Sriramulu, Antara Banerjee, M.K. Makalakshmi and Surajit Pathak*
Affiliation:
- Department of Medical Biotechnology, Faculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE), Chettinad Hospital and Research Institute (CHRI), Kelambakkam, Chennai 603103, Tamil Nadu,India
Keywords:
Conventional, therapeutics, colon cancer, overall survival, chemoradiotherapy, personalized medicine.
Abstract:
Background: Colon cancer is the second leading cause of cancer related deaths worldwide
with about 1.2 million new cases identified annually. While considering swift progress in the
field of molecular biology, new horizons in the treatment approaches have been materialized in colon
cancer with conventional methods being replaced with targeted therapies.
Methods: In this review, we focused on the existing conventional therapies utilized for colon cancer
by comparing the effectiveness of various standard/conventional therapies with respect to overall
survival parameter. Regardless of all the conventional treatments and scientific research, the disease
remains to be the one of the major cause of cancer related death and rising as societal burden due to
its co morbidities. Thus, we have also discussed briefly in this review, all the possible biotechnological
next-generation therapeutics including nucleic acid medicines, CRISPR-Cas9 technology, adoptive
cell therapy, cancer stem cells and therapy, gut microbiome, and personalized medicines, which
might be promising after effective clinical trials.
Results: From our study, we suggest that the use of neoadjuvant chemoradiotherapy in resected patients
was found to be safe and effective therapy in treating colon cancer and thereby improving
overall survival in patients. From considering the total estimate of our meta-analysis plot, we state
that the existing therapies are not much satisfying to improve the overall survival and more research
has to be carried out in this field to find an effective therapy to treat colon cancer.
Conclusions: As existing therapies are not much satisfying and are unable to improve the overall
survival, we brought together a diversity of possible approaches focusing on biotechnological nextgeneration
therapeutics to treat colon cancer. Hence, various multi-disciplinary choices are mandatory
in order to provide patients with distended access to tailored treatments.
